5-Nov-2025 6:00 AM CST - Business Wire Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the
4-Nov-2025 7:00 AM CST - Business Wire Geron Corporation to Present at Upcoming Investor Conferences Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in New York, NY 8th Annual Evercore Healthcare Conference Fireside chat on Tuesday, December 2 at 11:15 A
27-Oct-2025 7:00 AM CST - Business Wire Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A li
27-Aug-2025 3:05 PM CST - Business Wire Geron to Participate in the 2025 Wells Fargo Healthcare Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA. A live webcast of the presentation will be available at ir.geron.com and will be posted on the Investors and Media section of Gerons website. The webcast will be archived and available for replay for 30 days following t
6-Aug-2025 6:01 AM CST - Business Wire Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CEO. "We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as e
28-Jul-2025 7:00 AM CST - Business Wire Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time. A live we
7-May-2025 6:00 AM CST - Business Wire Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2025 and recent business highlights. "We are confident in the long-term potential of RYTELO as an important therapeutic for eligible patients with lower-risk-MDS and are sharply focused on maximizing the U.S. commercial opportunity, said Dawn Carter Bir, Inter
31-Mar-2025 3:30 PM CST - Business Wire Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day.
26-Feb-2025 6:30 AM CST - Business Wire Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated treatment with blockbuster potential in the high unmet need, lower-
5-Nov-2025 6:00 AM CST - Business Wire Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the
4-Nov-2025 7:00 AM CST - Business Wire Geron Corporation to Present at Upcoming Investor Conferences Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in New York, NY 8th Annual Evercore Healthcare Conference Fireside chat on Tuesday, December 2 at 11:15 A
27-Oct-2025 7:00 AM CST - Business Wire Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A li
27-Aug-2025 3:05 PM CST - Business Wire Geron to Participate in the 2025 Wells Fargo Healthcare Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA. A live webcast of the presentation will be available at ir.geron.com and will be posted on the Investors and Media section of Gerons website. The webcast will be archived and available for replay for 30 days following t
6-Aug-2025 6:01 AM CST - Business Wire Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CEO. "We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as e
28-Jul-2025 7:00 AM CST - Business Wire Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time. A live we
7-May-2025 6:00 AM CST - Business Wire Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2025 and recent business highlights. "We are confident in the long-term potential of RYTELO as an important therapeutic for eligible patients with lower-risk-MDS and are sharply focused on maximizing the U.S. commercial opportunity, said Dawn Carter Bir, Inter
31-Mar-2025 3:30 PM CST - Business Wire Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day.
26-Feb-2025 6:30 AM CST - Business Wire Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated treatment with blockbuster potential in the high unmet need, lower-
